72 Research Delivers Novel Therapeutic Antibodies For Rheumatoid Arthritis
ModiQuest Research has successfully generated novel antibody therapeutic leads and diagnostics for rheumatoid arthritis (RA). Using its extensive antibody generation technology platform, which includes phage display and high throughput mouse hybridoma generation, the company identified specific anti-citrulline antibodies that demonstrate high efficacy levels in preclinical RA models. The company has been especially successful in supporting a variety of autoimmune disease projects in addition to rheumatoid arthritis, including multiple sclerosis, and lupus erythematosus. By using a combination of a unique technology service platform and a growing collection of immunological reagents for autoimmune disease research, ModiQuest provides the antibody expertise, as well as customised antigens, monoclonal antibodies and enzymes specifically designed for early diagnosis as well as therapeutic research.
Research scientists at ModiQuest Research have definitive expertise in autoimmune disease allowing them to provide deep insights drawn from their own extensive experience in the field, and an unrivalled suite of products and services specifically aimed at supporting autoimmune disease research. Examples of autoimmune products and services that ModiQuest Research provides include: an effective mix of anti-collagen monoclonal antibodies for generating collagen antibody-induced arthritis (CAIA) in mice; readily available ELISA assay kits for evaluating autoimmune-associated peptide de-imination; custom development of diagnostic assays for other autoimmune disease pathways, and bespoke arthritis preclinical mouse efficacy studies for analyzing the therapeutic effects of client compounds in rheumatoid arthritis mouse models. “We have demonstrable success in generating anti-collagen antibody products for rheumatoid arthritis research and we have huge experience in the area of auto-immune and inflammatory disease” said Dr Jos Raats, CEO of ModiQuest Research. “We are currently helping a number of companies potentiate autoimmune therapies and diagnostic kits by the application of our antibody products and expertise.”
Circle no. 218 Do you
analyse,monitor ortestfor
Mercury?
28th July - 2nd August 2013, Edinburgh, Scotland Mercury as a Global Pollutant
The 11th International Conference on Mercury as a Global Pollutant returns after 10 years to Europe in 2013.
The event will be attract over 1000 International delegates and will discuss Scientific advances concerning mercury in the environment.
The 2013 meeting will be of particular importance as it coincides with the United Nations Environment Programme Global leagaly binding Treaty on Mercury.
Company and individuals who are interested in presenting, attending or exibiting should register their interest today.
www.mercury2013.com
Synbiosis is delighted to introduce its ProtoCOL 3 affordable colony counting and zone measurement system, the world’s first to automatically generate antibiotic and vaccine potency analysis from count and zone data.
The new ProtoCOL 3 system is designed for flexibility and accuracy and can read plates of 30 - 150mm, detecting colonies as small as 43 microns and measuring zones to 0.1mm, tasks which no other automated colony counter can achieve.
Additionally, the ProtoCOL 3 system’s unique tri- colour imaging method means performing challenging applications such as distinguishing grid lines on filters from colonies and counting black colonies on dark media are made quick and easy.
The system comes complete with software for basic colony counts and zone measurements. IQ, OQ and PQ documentation is also available to allow the system to be integrated into a GMP environment.
ProtoCOL 3 can be supplied with a computer or users can utilise their own and simply install the ProtoCOL 3 software.
For full statistical analysis, they can also add Synbiosis’s new European Pharmacopoeia/US Pharmacopeia compatible software to rapidly obtain potency data from their zone measurements or colony count results.
Martin Smith of Synbiosis commented: “Microbiologists want accurate automation for detecting barely visible colonies and zones. They also want simple set-up, the flexibility to read large and small plates, as well as the capability to rapidly generate statistical analysis from their results using just one system.”
+44 (0) 1727 858840
info@mercury2013.com Circle no. 219
Martin added: “This is challenging, but our new ProtoCOL 3 meets all these technical demands. We are confident that ProtoCOL 3 is now the best value for money, yet most advanced colony counting and zone sizing system and will benefit any microbiology laboratory wanting to increase their productivity.”
Circle no. 220
New Advanced Colony Counting and Zone Measurement System
INTERNATIONAL LABMATE - JANUARY/FEBRUARY 2012
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92
